MatthewRyanSharpeMD

Pulmonology • Kansas City, KS

Critical Care Medicine, Pleural Disease

Associate Professor, Internal Medicine, University Kansas School of Medicine Division of Pulmonary and Critical Care

Join to view full profile

Dr. Sharpe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sharpe's full profile

Already have an account?

Office
3901 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-588-6045
Is this information wrong?

Education & Training

University of Kansas School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007
University of Kansas School of MedicineResidency, Internal Medicine/Pediatrics, 2000 - 2004
University of Kansas School of MedicineClass of 2000

Certifications & Licensure

MO State Medical License 2021 - 2025
KS State Medical License 2002 - 2024
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

14 citations
Generation of pro-and anti-inflammatory mediators after acetaminophen overdose in surviving and non-surviving patients.
Benjamin L Woolbright, Nga T Nguyen, Mitchell R McGill, Matthew R Sharpe, Steven C Curry, Hartmut Jaeschke> ;Toxicology Letters. 2022 Aug 15
1 citations
Identifying the Role of the Respiratory Therapist on the Multidisciplinary Team in the Intensive Care Recovery Clinic.
Dave M Burnett, Matthew R. Sharpe> ;Respiratory Care. 2021 Dec 1
Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial.
Ellerbeck, E. F.,Nollen, N.,Hutcheson, T. D.,Phadnis, M.,Fitzgerald, S. A.,Vacek, J.,Sharpe, M. R.,Salzman, G. A.,Richter, K. P.> ;JAMA Netw Open. 2019 Jan 16
Glycodeoxycholic Acid Levels as Prognostic Biomarker in Acetaminophen-induced Acute Liver Failure Patients.
Woolbright, B. L.,McGill, M. R.,Staggs, V. S.,Winefield, R. D.,Gholami, P.,Olyaee, M.,Sharpe, M. R.,Curry, S. C.,Lee, W. M.,Jaeschke, H.> ;Toxicol. Sci.. 2014 Sep 23
Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome.
McGill, M. R.,Staggs, V. S.,Sharpe, M. R.,Lee, W. M.,Jaeschke, H.> ;Hepatology. 2014 Jun 14
Argininosuccinate synthetase as a plasma biomarker of liver injury after acetaminophen overdose in rodents and humans.
McGill, M. R.,Cao, M.,Svetlov, A.,Sharpe, M. R.,Williams, C. D.,Curry, S. C.,Farhood, A.,Jaeschke, H.,Svetlov, S. I.> ;Biomarkers. 2014 Mar 07
Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans.
Williams, C. D.,Bajt, M. L.,Sharpe, M. R.,McGill, M. R.,Farhood, A.,Jaeschke, H.> ;Toxicol. Appl. Pharmacol.. 2014 Jan 21
Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans.
McGill, M. R.,Li, F.,Sharpe, M. R.,Williams, C. D.,Curry, S. C.,Ma, X.,Jaeschke, H.> ;Arch. Toxicol.. 2013 Aug 28
Lysosomal Instability and Cathepsin B Release during Acetaminophen Hepatotoxicity.
Woolbright, B. L., Ramachandran, A., McGill, M. R., Yan, H. M., Bajt, M. L., Sharpe, M. R., Lemasters, J. J., Jaeschke, H.> ;Basic Clin Pharmacol Toxicol. 2012 Dec
Join now to see all

Hospital Affiliations

The University of Kansas HospitalKansas City, Kansas